[AMAG] AMAG Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 35.8 Change: 1 (2.87%)
Ext. hours: Change: 0 (0%)

chart AMAG

Refresh chart

Strongest Trends Summary For AMAG

AMAG is in the long-term down -83% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep

Fundamental Ratios
Shares Outstanding EPS1.11 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 385.93% Sales Growth - Q/Q38.41% P/E14.77
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA11.63% ROE26.74% ROI15.98%
Current Ratio1.71 Quick Ratio1.61 Long Term Debt/Equity1.51 Debt Ratio0.45
Gross Margin81.03% Operating Margin31.1% Net Profit Margin65.25% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities183.64 M Cash From Investing Activities-284.74 M Cash From Operating Activities71.69 M Gross Profit104.2 M
Net Profit33.26 M Operating Profit61.12 M Total Assets1.64 B Total Current Assets555.48 M
Total Current Liabilities323.97 M Total Debt483.2 M Total Liabilities926.3 M Total Revenue123.88 M
Technical Data
High 52 week25.65 Low 52 week10.34 Last close10.34 Last change-4.08%
RSI40.26 Average true range0.72 Beta0.76 Volume768.3 K
Simple moving average 20 days-8.89% Simple moving average 50 days-14.38% Simple moving average 200 days-41.9%
Performance Data
Performance Week-10.32% Performance Month-13.18% Performance Quart-38.12% Performance Half-56.92%
Performance Year-21.96% Performance Year-to-date-31.93% Volatility daily4.01% Volatility weekly8.97%
Volatility monthly18.39% Volatility yearly63.7% Relative Volume235.39% Average Volume747.72 K
New High New Low


2019-09-12 08:00:00 | AMAG Sends Letter to Shareholders

2019-09-06 09:31:01 | Why Is AMAG Pharmaceuticals AMAG Up 27.3% Since Last Earnings Report?

2019-09-05 06:24:51 | Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag

2019-09-04 17:56:11 | AMAG Urges Stockholders to Take No Action on Caligan Partners’ Consent Solicitation Materials

2019-09-04 09:45:46 | Activist Investor Seek Four Board Seats at Amag Pharmaceuticals

2019-08-27 08:00:00 | AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ Bremelanotide Injection

2019-08-20 08:00:00 | AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635c4

2019-08-16 10:42:02 | Palatin's PTN to Report Q4 Earnings: What's in the Cards?

2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say

2019-08-15 14:23:00 | [video]New York Investment Firm Discloses 10.3% Amag Stake, May Propose Changes

2019-08-14 13:39:58 | Have Insiders Been Buying AMAG Pharmaceuticals, Inc. NASDAQ:AMAG Shares?

2019-08-13 11:42:22 | Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More


2019-08-12 16:00:00 | Why AMAG Pharmaceuticals Stock Jumped Today

2019-08-09 09:41:35 | AMAG Pharmaceuticals Inc AMAG Q2 2019 Earnings Call Transcript

2019-08-08 11:20:03 | AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

2019-08-07 17:36:34 | Edited Transcript of AMAG earnings conference call or presentation 7-Aug-19 12:00pm GMT

2019-08-07 15:00:00 | What's Behind AMAG Pharmaceuticals' Horrible Q2 Results

2019-08-07 08:35:12 | AMAG Pharmaceuticals AMAG Reports Q2 Loss, Misses Revenue Estimates

2019-08-07 07:00:00 | AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-08-06 12:50:42 | UPDATE 1-Amag's female libido injectable therapy to sell at $899

2019-08-06 12:43:44 | Amag's female libido injectable therapy to sell at $899

2019-07-31 10:36:02 | AMAG Pharmaceuticals AMAG May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-07-29 08:00:00 | AMAG Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, August 7, 2019 at 8:00 a.m. ET

2019-07-25 10:33:02 | Will AMAG Pharmaceuticals AMAG Report Negative Q2 Earnings? What You Should Know

2019-07-23 09:29:01 | AMAG AMAG to Report Q2 Earnings: What's in the Cards?

2019-07-09 15:07:43 | Calculating The Intrinsic Value Of AMAG Pharmaceuticals, Inc. NASDAQ:AMAG

2019-07-04 08:35:12 | Alexion's Ultomiris Receives EU Approval for PNH in Adults

2019-06-28 13:03:09 | Largest Insider Trades of the Week

2019-06-27 12:55:59 | Here’s What Hedge Funds Think About AMAG Pharmaceuticals, Inc. AMAG

2019-06-26 08:37:12 | Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

2019-06-25 15:49:00 | Why Palatin Technologies Stock Dropped as Much as 21.5% Today

2019-06-25 14:00:00 | How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug

2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

2019-06-24 16:19:00 | Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women

2019-06-24 13:58:00 | Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

2019-06-24 08:03:00 | Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

2019-06-22 15:07:43 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-06-21 17:41:00 | AMAG stock rallies on FDA approval for drug to increase women's sex drive

2019-06-21 17:37:37 | Amag’s plan to bypass female libido drug pitfalls? Social media.

2019-06-21 17:23:08 | AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ Bremelanotide Injection for Acquired, Generalized Hypoactive Sexual Desire Disorder HSDD in Premenopausal Women

2019-06-20 09:00:01 | All You Need to Know About AMAG Pharmaceuticals AMAG Rating Upgrade to Buy

2019-06-10 09:39:01 | TherapeuticsMD Enters Agreement to Market Drugs Outside US

2019-06-06 09:31:01 | AMAG Pharmaceuticals AMAG Down 8.9% Since Last Earnings Report: Can It Rebound?

2019-06-05 15:45:00 | AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid

2019-05-29 08:00:00 | AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

2019-05-20 15:15:07 | Is AMAG Pharmaceuticals, Inc.'s NASDAQ:AMAG Balance Sheet A Threat To Its Future?

2019-05-20 05:21:09 | New Strong Sell Stocks for May 20th

2019-05-17 08:00:00 | AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York

2019-05-10 10:31:02 | New Strong Sell Stocks for May 10th